Cargando…
Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism
BACKGROUND: Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when administered as a short‐acting preparation. OBJEC...
Autores principales: | Gostelow, R., Scudder, C., Keyte, S., Forcada, Y., Fowkes, R.C., Schmid, H.A., Church, D.B., Niessen, S.J.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354018/ https://www.ncbi.nlm.nih.gov/pubmed/28145031 http://dx.doi.org/10.1111/jvim.14662 |
Ejemplares similares
-
Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015) -
Efficacy of hypophysectomy for the treatment of hypersomatotropism‐induced diabetes mellitus in 68 cats
por: Fenn, Joe, et al.
Publicado: (2021) -
Serum N‐Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism
por: Keyte, S.V., et al.
Publicado: (2016) -
Hypersomatotropism in 3 Cats without Concurrent Diabetes Mellitus
por: Fletcher, J.M., et al.
Publicado: (2016) -
Epidemiology of Diabetes Mellitus among 193,435 Cats Attending Primary‐Care Veterinary Practices in England
por: O'Neill, D.G., et al.
Publicado: (2016)